Skip to main content
Premium Trial:

Request an Annual Quote

OGT, Two UK Facilities to Develop Array-Based STD Dx; Prototype Planned in One Year

NEW YORK (GenomeWeb News) — Oxford Gene Technology, St. George’s University of London, and St. George’s Healthcare NHS plan to develop a single-platform microarray that could “diagnose multiple sexually transmitted [diseases],” OGT said today.
OGT said the test would have the capacity to diagnose many STD pathogens in a single specimen and would offer cost-effective results on the same day. It did not elaborate.
The company hopes eventually to develop the technology into accurate, point-of-care testing that would detect many STDs. But first it hopes to have a prototype after one year, at which point it plans to begin validating the array using clinical samples.
OGT said it will couple its microarray services with PCR amplification and also may use its multi sample array format in efforts to reduce the cost per sample and speed up the diagnostic process.
Tariq Sadiq, a urinary specialist and a senior lecturer at St. George’s, said STDs directly cost the UK’s National Health Service £1 billion ($1.9 billion) a year. “If successful, we think the microarray may be an important tool in the attempts to reduce the burden of STDs and their transmission,” Sadiq said.
OGT and the Heptagon Proof of Concept Fund will fund the program.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.